SCHEMBL1865963

SCHEMBL1865963

CC(C)(C)OC(=O)N1CCC(=Cc2cc3nc(Cl)nc(N4CCOCC4)c3s2)CC1

nearest known ligand 0.42

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 9/20 0.42
PIK3R1 P27986 5/20 0.42
PIK3CD O00329 5/20 0.42
SMN1; SMN2 Q16637 2/20 0.40
USP2 O75604 1/20 0.40
MTOR P42345 5/20 0.38
RECQL P46063 1/20 0.38
PIK3CB P42338 2/20 0.37
PIK3CG P48736 2/20 0.37
SYK P43405 1/20 0.37
MAP3K9 P80192 1/20 0.37
GRM5 P41594 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2672415 0.93 PIK3CD (0.43) PIK3CAPIK3R1PIK3CDSMN1; SMN2USP2
SCHEMBL1856015 0.82 PIK3CA (0.47) PIK3CAPIK3R1PIK3CDSMN1; SMN2MTOR
SCHEMBL1300511 0.82 KIT (0.51) PIK3CAPIK3R1PIK3CDSMN1; SMN2USP2
SCHEMBL1284511 0.81 GBA1 (0.43) PIK3CAPIK3CD
SCHEMBL1867260 0.81 PIK3CA (0.42) PIK3CAPIK3R1PIK3CDSMN1; SMN2USP2
SCHEMBL466290 0.81 PIK3CD (0.52) PIK3CAPIK3R1PIK3CDMTORPIK3CB
SCHEMBL2271549 0.80 SMN1; SMN2 (0.40) PIK3CAPIK3R1PIK3CDSMN1; SMN2USP2
SCHEMBL1860950 0.79 PIK3CD (0.41) PIK3CAPIK3R1PIK3CDSMN1; SMN2USP2
SCHEMBL1870346 0.78 PIK3CA (0.41) PIK3CAPIK3R1PIK3CDSMN1; SMN2MTOR
SCHEMBL1867692 0.78 PIK3CA (0.45) PIK3CAPIK3R1PIK3CDSMN1; SMN2USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2046799-B1 PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM GENENTECH INC (US) 2017-07-19 EP disclosed
US-8450315-B2 Phosphoinositide 3-kinase inhibitor compounds and methods of use GENENTECH, INC. (US) 2013-05-28 US disclosed
US-20110105464-A1 PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE GENENTECH, INC. 2011-05-05 US disclosed
US-7846929-B2 Using 1-(4-((2-(aminopyrimidin-5-yl)-4-morpholinothieno(3,2-d)pyrimidin-6-yl)methyl)piperazin-1-yl)-2-(methylsulfonyl)ethanone; lipid kinase inhibitor; anticancer agents ; antiinflammatory agents; antidiabetic agents GENENTECH, INC. (US) 2010-12-07 US disclosed
EP-2046799-A1 PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Genentech, Inc. (US) 2009-04-15 EP disclosed
US-20080039459-A1 Phosphoinositide 3-kinase inhibitor compounds and methods of use PLRAMED LIMITED (GB) 2008-02-14 US disclosed
WO-2007127183-A1 PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM GENENTECH, INC. (US) 2007-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105464-A1 PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE PI4KB, PIK3CB, PIK3C2B PIK3CA 6/4885PIK3R1 25/4885PIK3CD 10/4885
US-20080039459-A1 Phosphoinositide 3-kinase inhibitor compounds and methods of use PIK3CA, PI4KB, PI4KA PIK3CA 1/4885PIK3R1 27/4885PIK3CD 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.